5 August 2019 - Specialised Therapeutics, an Australian biopharmaceutical company and Alimera’s distribution partner, to next seek national reimbursement.

Alimera Sciences announces today that the Australian Therapeutic Goods Administration, the division of the Australian Department of Health that oversees the availability of medical products, has approved Iluvien (190 micrograms intra-vitreal implant in applicator) for the treatment of diabetic macular oedema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intra-ocular pressure.

Read Alimera Sciences press release